Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy Volunteers
Vance L. Albaugh, Ravi Singareddy, David Mauger, et al.
PLoS ONE (2011) Vol. 6, Iss. 8, pp. e22662-e22662
Open Access | Times Cited: 107

Showing 26-50 of 107 citing articles:

The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis
Bing Bai, Yuwei Li, Xi Chen, et al.
BMC Psychiatry (2025) Vol. 25, Iss. 1
Open Access
Cardiometabolic Risk Indicators That Distinguish Adults with Psychosis from the General Population, by Age and Gender
Debra L. Foley, Andrew Mackinnon, Gerald F. Watts, et al.
PLoS ONE (2013) Vol. 8, Iss. 12, pp. e82606-e82606
Open Access | Times Cited: 50
Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats
Heidi N. Boyda, Alfredo Ramos‐Miguel, Ric M. Procyshyn, et al.
The International Journal of Neuropsychopharmacology (2013) Vol. 17, Iss. 01, pp. 77-90
Open Access | Times Cited: 48
Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects
Teresa Cabaleiro, Rosario López‐Rodríguez, Dolores Ochoa, et al.
Human Psychopharmacology Clinical and Experimental (2013) Vol. 28, Iss. 3, pp. 205-214
Closed Access | Times Cited: 47
Obesity exacerbates the acute metabolic side effects of olanzapine
Logan K. Townsend, Willem T. Peppler, Natasha Bush, et al.
Psychoneuroendocrinology (2017) Vol. 88, pp. 121-128
Closed Access | Times Cited: 46
Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation
Clare Whicher, Hermione Price, R. I. G. Holt
European Journal of Endocrinology (2018) Vol. 178, Iss. 6, pp. R245-R258
Open Access | Times Cited: 40
Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy
Donghong Cui, Yanmin Peng, Chengfang Zhang, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 11, pp. 4997-5007
Open Access | Times Cited: 40
Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism
L Castellani, Kenya A. Costa-Dookhan, William Brett McIntyre, et al.
Journal of Psychiatry and Brain Science (2019)
Open Access | Times Cited: 40
Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives
Shen-Chieh Chang, Kah Kheng Goh, Mong‐Liang Lu
World Journal of Psychiatry (2021) Vol. 11, Iss. 10, pp. 696-710
Open Access | Times Cited: 30
Antipsychotic-Induced Alterations in Lipid Turnover
Sandra Pereira, Emily Au, Sri Mahavir Agarwal, et al.
Endocrinology (2023) Vol. 164, Iss. 4
Open Access | Times Cited: 11
Genetics of antipsychotic-induced weight gain: update and current perspectives
Amy CC Kao, Daniel J. Müller
Pharmacogenomics (2013) Vol. 14, Iss. 16, pp. 2067-2083
Closed Access | Times Cited: 41
Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine
Heidi N. Boyda, Ric M. Procyshyn, Catherine C.Y. Pang, et al.
PLoS ONE (2013) Vol. 8, Iss. 1, pp. e53459-e53459
Open Access | Times Cited: 39
Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain
Johan Fernø, Kari M. Ersland, I.H. Duus, et al.
European Neuropsychopharmacology (2015) Vol. 25, Iss. 6, pp. 923-932
Closed Access | Times Cited: 38
Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia
L Castellani, Willem T. Peppler, Charles Sutton, et al.
Psychoneuroendocrinology (2017) Vol. 82, pp. 38-45
Closed Access | Times Cited: 33
Effects of second-generation antipsychotics on human subcutaneous adipose tissue metabolism
Assel Sarsenbayeva, Cátia M. Marques-Santos, Ketan Thombare, et al.
Psychoneuroendocrinology (2019) Vol. 110, pp. 104445-104445
Open Access | Times Cited: 33
Dietary intake, physical activity and sedentary behaviour patterns in a sample with established psychosis and associations with mental health symptomatology
Rebecca Martland, Scott Teasdale, Robin M. Murray, et al.
Psychological Medicine (2021) Vol. 53, Iss. 4, pp. 1565-1575
Open Access | Times Cited: 24
Second-Generation Antipsychotics Cause a Rapid Switch to Fat Oxidation That Is Required for Survival in C57BL/6J Mice
Candice M. Klingerman, Michelle E. Stipanovic, Michael Bäder, et al.
Schizophrenia Bulletin (2013) Vol. 40, Iss. 2, pp. 327-340
Open Access | Times Cited: 36
Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta‐analysis
Renee‐Marie Ragguett, Margaret Hahn, Giovanni Messina, et al.
Human Psychopharmacology Clinical and Experimental (2017) Vol. 32, Iss. 6
Closed Access | Times Cited: 31
Brain insulin action: Implications for the treatment of schizophrenia
Sri Mahavir Agarwal, Chantel Kowalchuk, L Castellani, et al.
Neuropharmacology (2019) Vol. 168, pp. 107655-107655
Closed Access | Times Cited: 28
Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis
Rong Li, Yiqi Zhang, Wenqiang Zhu, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 26
Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs
Julia M. Gohlke
Frontiers in Psychiatry (2012) Vol. 3
Open Access | Times Cited: 31
Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance
Gary Remington, Celine Teo, Virginia Wilson, et al.
Journal of Endocrinology (2015) Vol. 227, Iss. 2, pp. 71-81
Open Access | Times Cited: 26
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo
Jacob S. Ballon, Utpal B. Pajvani, Laurel Mayer, et al.
Journal of Psychopharmacology (2018) Vol. 32, Iss. 5, pp. 533-540
Open Access | Times Cited: 26
H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice
Magdalena Dudek, Kamil Kuder, Marcin Kołaczkowski, et al.
Metabolic Brain Disease (2016) Vol. 31, Iss. 5, pp. 1023-1029
Open Access | Times Cited: 25
Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines
Heidi N. Boyda, Amanzo A. Ho, Lurdes Tse, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 22

Scroll to top